INTRODUCTION
cancer deaths, PDAC, Abemaciclib
PANCREATIC DUCTAL ADENOCARCINOMA
Pancreatic ductal adenocarcinoma (PDAC) is highly lethal and the fourth leading cause of cancer deaths worldwide, with a 5‐year survival of only 10%.
Preclinical data with the CDK4/6 inhibitors, palbociclib and abemaciclib, demonstrated variable single‐agent efficacy in PDAC models.Abemaciclib is a potent, selective small‐molecule CDK4/6 inhibitor and is FDA‐approved as monotherapy and in combination with endocrine therapy for hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2‐) advanced breast cancer,Given the relevance of the CDK4/6 pathway in PDAC, the preclinical activity of CDK4/6 inhibition in PDAC models, including in 